KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Short term Debt (2019 - 2026)

Castle Biosciences' Short term Debt history spans 5 years, with the latest figure at $417000.0 for Q4 2025.

  • On a quarterly basis, Short term Debt rose 50.0% to $417000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $417000.0, a 50.0% increase, with the full-year FY2025 number at $417000.0, up 50.0% from a year prior.
  • Short term Debt hit $417000.0 in Q4 2025 for Castle Biosciences, down from $1.9 million in the prior quarter.
  • Over the last five years, Short term Debt for CSTL hit a ceiling of $20.8 million in Q1 2022 and a floor of $278000.0 in Q4 2024.
  • Historically, Short term Debt has averaged $4.9 million across 3 years, with a median of $1.1 million in 2025.
  • The widest YoY moves for Short term Debt: up 50.0% in 2025, down 50.0% in 2025.
  • Tracing CSTL's Short term Debt over 3 years: stood at $20.8 million in 2022, then plummeted by 98.67% to $278000.0 in 2024, then soared by 50.0% to $417000.0 in 2025.
  • Business Quant data shows Short term Debt for CSTL at $417000.0 in Q4 2025, $1.9 million in Q2 2025, and $1.1 million in Q1 2025.